<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013502</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-61538</org_study_id>
    <nct_id>NCT05013502</nct_id>
  </id_info>
  <brief_title>Empagliflozin in Diuretic Refractory Ascites</brief_title>
  <acronym>DRAin-Em 01</acronym>
  <official_title>Management of Diuretic Refractory Ascites in Cirrhosis With Empagliflozin (DRAin-Em-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ascites is the most frequent complication of liver cirrhosis and results in increased&#xD;
      morbidity and mortality but current medical management options are limited. Here, the&#xD;
      investigators will conduct an interventional single-arm pilot clinical trial toevaluate the&#xD;
      feasibility of empagliflozin in managing diuretic-resistant ascites in patients with&#xD;
      decompensated cirrhosis. This single site, open label pilot study will enroll participants&#xD;
      with decompensated cirrhosis at a single site. Participants will receive empagliflozin 10mg&#xD;
      oral tablets once daily for 12 weeks with monitoring for safety and adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacologic options for the management of ascites are limited to diuretics only. Each year&#xD;
      approximately 10% of patients with cirrhosis develop diuretic-resistant ascites,&#xD;
      necessitating the use of more invasive procedures such a paracentesis, transjugular&#xD;
      intrahepatic portosystemic shunting (TIPS), and transplantation; each modality is associated&#xD;
      with significant risks and limitations. Patients treated with diuretics may also develop&#xD;
      complications such as acute kidney injury, encephalopathy, muscle cramping, or hyponatremia,&#xD;
      limiting optimal dosages of these medications and hence, resulting in inadequate control of&#xD;
      fluid retention. Thus, ascites that is resistant to our current therapies is an important&#xD;
      unmet medical need.&#xD;
&#xD;
      Recently, SGLT2-Is have been shown to reduce heart failure hospitalizations and&#xD;
      cardiovascular death in patients with and without diabetes in landmark, large-scale clinical&#xD;
      trials. Empagliflozin improved heart failure outcomes without altering hemoglobin A1c or&#xD;
      increasing risk of hypoglycemia in individuals without diabetes, suggesting that SGLT2-Is may&#xD;
      act through a neurohormonal mechanism independent of blood glucose changes. Because cirrhosis&#xD;
      and heart failure are disorders with a common pathophysiology of decreased effective arterial&#xD;
      blood volume with resultant stimulation of the renin-angiotensin-aldosterone system (RAAS),&#xD;
      sympathetic nervous system, and total body fluid overload, the investigators hypothesize that&#xD;
      SGLT2-Is may be effective in the management of ascites. Multiple lines of evidence suggest&#xD;
      SGLT2-Is may have a beneficial role in chronic liver disease. Several case reports of&#xD;
      patients with cirrhosis and diuretic-resistant ascites have found that SGLT2-I treatment was&#xD;
      associated with near resolution of ascites and pedal edema. SGLT2-I treatment has also&#xD;
      demonstrated improved hepatic function, reduction of fibrosis and normalization of liver&#xD;
      enzymes in non-alcoholic fatty liver disease (NAFLD).Although SGLT2-I are partially cleared&#xD;
      by the liver, empagliflozin is well tolerated in patients with cirrhosis. Thus, the&#xD;
      investigators initiated a feasibility study to test the hypothesis that the SGLT2-I,&#xD;
      empagliflozin, will decrease ascites by attenuating maladaptive neurohormonal and&#xD;
      inflammatory responses in cirrhosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant retention rate as a measure of study feasibility</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Retention rate and completion of trial activities through 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in abdominal girth from baseline to 12 weeks</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Abdominal girth as a measure of ascites volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in body weight from baseline to 12 weeks</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Body weight as a measure of ascites volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in patient reported functional status</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Functional status and quality of life measured on SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate as a measure of kidney function</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in renal function as measured by serum creatinine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <condition>Ascites Hepatic</condition>
  <condition>Sodium-Glucose Transporter 2 Inhibitors</condition>
  <arm_group>
    <arm_group_label>Empagliflozin 10mg PO daily for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>empagliflozin 10mg PO once daily</description>
    <arm_group_label>Empagliflozin 10mg PO daily for 12 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Decompensated liver cirrhosis with ascites&#xD;
&#xD;
          -  Diuretic-resistant ascites defined as one of the following: a) An inability to&#xD;
             mobilize ascites despite adherence to dietary sodium restriction (2000 mg per day) and&#xD;
             administration of maximum tolerable doses of oral diuretics; b) Rapid reaccumulation&#xD;
             of fluid after therapeutic paracentesis despite adherence to a sodium-restricted diet.&#xD;
             c) Development of diuretic-related complications such as progressive azotemia, hepatic&#xD;
             encephalopathy, or progressive electrolyte imbalances&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to any SGLT2 inhibitor&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  eGFR below 45mL/min/1.73m2 or decrease in eGFR by &gt;30% between screening&#xD;
&#xD;
          -  Recurrent urinary tract infections or recurrent genitourinary fungal infections,&#xD;
             defined as &gt; 2 infections in six months or &gt;3 infections in one year&#xD;
&#xD;
          -  Hypotension requiring oral vasopressor therapy&#xD;
&#xD;
          -  Patients with particular risk for ketoacidosis including active moderate or severe&#xD;
             alcohol use disorder, pancreatitis, pancreatic insulin deficiency from any cause, or&#xD;
             episode of ketoacidosis in the past&#xD;
&#xD;
          -  History of skin or soft tissue infection requiring IV antibiotics including Fornier's&#xD;
             gangrene or prior limb amputation&#xD;
&#xD;
          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,&#xD;
             makes them an unreliable trial subject or unlikely to complete the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aparna Goel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vyvian Ngo, MPH</last_name>
    <phone>650-498-9125</phone>
    <email>vyviann@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Branden D Tarlow, MD PhD</last_name>
    <phone>(650) 498-7111</phone>
    <email>tarlow@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Digestive Health Clinic</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94060</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Vyvian Ngo, MPH</last_name>
      <phone>650-498-9125</phone>
      <email>vyviann@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Branden Tarlow, MD Phd</last_name>
      <phone>650-736-5555</phone>
      <email>tarlow@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aparna Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Branden Tarlow, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Kwo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Aparna Goel</investigator_full_name>
    <investigator_title>Protocol Director</investigator_title>
  </responsible_party>
  <keyword>diuretic refractory</keyword>
  <keyword>diuretic resistant</keyword>
  <keyword>empagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

